この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2025/12/81 分で読めます
Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic; Availability
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA or Agency) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Genentech, Inc. (Genentech) for Actemra (tocilizumab). FDA revoked this Authorization on August 8, 2025, under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The revocation, including an explanation of the reasons for the revocation, are reprinted in this document.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →